Contract
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
Exhibit 10.1
24 May 2016
|
(1) |
XXXX XXXXXXX LIMITED |
and
|
(2) |
VERSARTIS GMBH |
_________________________________
MANUFACTURING AND SUPPLY AGREEMENT
_________________________________
THIS AGREEMENT is made on the 24th day of May 2016 (the “Agreement”)
BETWEEN
(1) |
XXXX XXXXXXX LIMITED, a company incorporated in England and Wales with registration number 1257871 whose registered office address is at Xxxxx Xxxx, Xxxxxxxxx, Xxxxxx XX00 0XX, XX (“Xxxx Xxxxxxx”); and |
(2) |
VERSARTIS GMBH, a limited liability company registered in Switzerland whose principal place of business is at Xxxxxxxxxx 0, 0000 Xxxxx, Xxxxxxxxxxx (the “Customer”). |
BACKGROUND
(A) |
Xxxx Xxxxxxx is a world leader in the development and manufacture of medical devices for, amongst other things, drug delivery. |
(B) |
The Customer is a subsidiary of Versartis, Inc., a pharmaceutical company developing drug products including a long-acting form of recombinant human growth hormone. |
(C) |
The Customer wishes to appoint and Xxxx Xxxxxxx wishes to accept the appointment from the Customer to manufacture and supply drug delivery devices and units of combination product containing such device and drug supplied by Customer for the Customer on the terms of this Agreement. |
(D) |
The Customer will supply to Xxxx Xxxxxxx the active pharmaceutical ingredient in prefilled syringes and certain other materials which will be incorporated by Xxxx Xxxxxxx into the drug delivery device as set out in this Agreement. |
OPERATIVE PROVISIONS
Affiliate |
means any company or other entity which directly or indirectly controls, is controlled by or is under common control with a party, where ‘control’ means the ownership of more than 50% of the issued share capital or other equity interest or the legal power to direct or cause the direction of the general management and policies of that party or such company or other entity;
|
Authorised Sub-contractor
|
means any sub-contractor for the supply of the Device or Final Combination Product on a temporary basis under clause 4.3, as agreed between the parties from or alternatively as listed in the Quality Agreement;
|
Business Days |
means Monday to Friday (inclusive) except bank or public holidays in England and in the United States of America;
|
-2 -
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
means a listing of all results for tests conducted on samples of a lot of the Device or the Final Combination Product compared to the specifications defined by the Customer and listed in the regulatory applications;
|
|
Certificate of Conformity |
means a signed certificate issued by Xxxx Xxxxxxx certifying the conformity of a batch of Devices with the Specification and GMP (but excluding certification of any testing or inspection of the Drug or its syringe beyond visual inspection for damage or discoloration);
|
Confidential Information |
means, in relation to each party, (i) all information in any form or medium disclosed by that party (the “disclosing party”) to the other party (the “receiving party”) under or in connection with this Agreement whether before, on or after the Effective Date, and (ii) the terms of this Agreement;
|
Customer Materials |
means all materials (including the Drug) supplied by the Customer to Xxxx Xxxxxxx;
|
Device |
means the auto-injector device as described in Part 1 of Schedule 1, or any similar auto-injector device incorporating design features within the scope of the patents or other intellectual property covering the combination of features described in Part 1 of Schedule 1, in each case solely for use in the Field;
|
Drug |
means the long-acting form of human growth hormone known as somavaratan (or VRS-317);
|
Effective Date |
means the date set out at the top of this Agreement;
|
Exchange Rate |
means the Bank of England’s published mid-market exchange rate of UK Pounds Sterling to U.S. Dollars;
|
Exchange Rate Comparison Date |
means whichever is the later of the Effective Date or the latest date on which any amendment of the Price was effected under clause 10.5;
|
Field
|
means treatment of human growth hormone deficiency and any other condition for which any human growth hormone product is approved in the Territory, including but not limited to idiopathic short stature (ISS), small for gestational age (SGA), Prader-Willi syndrome (PWS), and Xxxxxx syndrome using any human growth hormone product or analogue;
|
-3 -
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
|
means the product produced by Xxxx Xxxxxxx using the Device and Customer Materials (including the Drug) as described in Part 3 of Schedule 1 and as labelled and packaged in accordance with Part 2 of Schedule 1 (and for the avoidance of doubt for the purposes of the purchase commitment in clause 2.3 a Final Combination product shall include any product comprising a Device and a Drug);
|
GMP |
means the principles of good manufacturing practice as set out in EC Directive 93/42/EEC, EC Directive 2003/94 and/or CRF title 21 part 210, 211 and 820 each as amended from time to time, or any successors to them and any other applicable regulations;
|
Intellectual Property Rights |
means patent applications, patents, rights to inventions, copyright and related rights, trademarks, trade names and domain names, rights in designs, rights in computer software, database rights, rights in confidential information (including know-how) and any other intellectual property rights, in each case whether registered or unregistered and including all applications (or rights to apply) for, and renewals or extensions of, such rights and all similar or equivalent rights or forms of protection which subsist or will subsist now or in the future in any part of the world;
|
Limited Field
|
means the treatment of human growth hormone deficiency and all other analogous conditions using a long-acting human growth hormone or analogous product dosed once weekly or less frequently;
|
Minimum Order Quantity
|
means [*] units of the Final Combination Product;
|
Price |
means the fee payable by the Customer in relation to the supply of each unit of the Final Combination Product to the Customer as set out in Schedule 2;
|
Primary Packaging
|
means packaging that envelops the Final Combination Product and retains such Final Combination Product as described in Part 2 of Schedule 1;
|
Purchase Order |
means a written order for Final Combination Product received by Xxxx Xxxxxxx from the Customer;
|
-4 -
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
1.2 |
In this Agreement: |
|
1.2.1 |
references to clauses are to the clauses of this Agreement; |
|
1.2.2 |
references to the parties are to the parties to this Agreement; |
|
1.2.3 |
headings are used for convenience only and do not affect its interpretation; and |
|
1.2.4 |
references to a statutory provision include references to the statutory provision as modified or re-enacted or both from time to time and to any subordinate legislation made under the statutory provision. |
2.1 |
During the Term of this Agreement: |
|
2.1.1 |
Xxxx Xxxxxxx agrees to manufacture the Device, to assemble the Device with the Customer Materials and to supply the Final Combination Product to the Customer each in accordance with the Specifications. |
|
2.3.1 |
the Customer’s entire requirement for the Final Combination Product in respect of territories and countries outside the European Economic Area during the entirety of the Term; and |
-5 -
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
2.5 |
During the Term the Customer will provide Xxxx Xxxxxxx with Customer Materials in bulk packaging as required for the production of the Final Combination Product. |
|
2.6.1 |
for any conflicts related to quality assurance matters or the regulatory obligations of the parties, or any Specifications, the Quality Agreement shall prevail; and |
|
2.6.2 |
for all other conflicts, this Agreement shall prevail. |
-6 -
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
applicable laws and regulations and shall obtain the Customer’s prior agreement in writing before making any such change. |
2.9 |
The Customer shall inform Xxxx Xxxxxxx in writing at as early as stage as possible of any proposed changes to any of the Customer Materials (including without limitation any change to their specifications, design or composition) or and change of applicable laws and regulations relating to the Customer Materials, and the parties shall thereafter discuss in good faith how best to accommodate such change (including without limitation by varying this Agreement or any relevant Specifications). |
2.10 |
Xxxx Xxxxxxx agrees to comply with any reasonable instructions provided by the Customer (to the extent they are consistent with the Quality Agreement) in relation to the incorporation of any Customer Materials into the Final Combination Product and in relation to the Primary and Secondary Packaging and inclusion or affixation of any labelling, leaflets and/or trademarks in or to the Final Combination Product as specified in Part 2 of Schedule 1. |
|
2.12.2 |
Xxxx Xxxxxxx shall provide the List to Customer within two (2) weeks following the Effective Date and shall notify Customer of any new approved suppliers added to the List within two (2) weeks of their addition; and |
|
2.12.3 |
Xxxx Xxxxxxx shall oblige each subcontractor to comply with the relevant provisions of this Agreement and remains liable to the Customer for the performance of its obligations under this Agreement, whether or not sub-contracted. |
3.1 |
The Customer will co-operate with Xxxx Xxxxxxx as may reasonably be requested by Xxxx Xxxxxxx relating to the manufacture of the Devices and the assembly and supply of Final Combination Product and will respond in a timely manner to all reasonable requests for information from Xxxx Xxxxxxx. |
-7 -
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
3.3 |
The Customer will supply, or procure the supply to Xxxx Xxxxxxx of all Customer Materials as may be reasonably required by Xxxx Xxxxxxx together with material safety data sheets and any other information reasonably necessary to ensure safe storage and handling of them by Xxxx Xxxxxxx. The Customer shall, or Customer’s designated representative shall, deliver the Customer Materials to Xxxx Xxxxxxx Delivered At Place (INCOTERMS 2010) at Chipping Norton, UK. Xxxx Xxxxxxx agrees to only use the Customer Materials as required for the manufacture of the Devices and the assembly and supply of the Final Combination Product to the Customer in accordance with the terms of this Agreement and agrees not to: |
|
3.3.1 |
use the Customer Materials for any commercial purpose except for the manufacture of the Devices and the assembly and supply of the Final Combination Product; or |
|
3.3.2 |
not to distribute any of the Customer Materials to any third party other than an Affiliate or sub-contractor of Xxxx Xxxxxxx as necessary for the performance of this Agreement. |
3.4 |
The Customer shall provide Customer Materials to Xxxx Xxxxxxx as are necessary for the manufacture of the Devices and the assembly of the Final Combination Product in accordance with this Agreement. Xxxx Xxxxxxx understands and acknowledges that the Customer Materials: may have hazardous properties and must be handled and used with due care in accordance with the instructions provided by the Customer, taking into account the potentially hazardous nature of the Customer Materials and any procedures notified to Xxxx Xxxxxxx by the Customer (which may be changed by the Customer from time to time following reasonable notice to Xxxx Xxxxxxx) and in accordance with all applicable laws and safety regulations. |
3.5 |
All Customer Materials are stored at Customer’s risk, and the Customer is responsible for insuring against all loss or damage to the Customer Materials while in Xxxx Xxxxxxx’x possession. If Customer Materials are damaged in storage, Xxxx Xxxxxxx shall inform the Customer of such damage as soon as reasonably possible and in no event later than forty-eight (48) hours from the time such damage is discovered by Xxxx Xxxxxxx. Following such notification the parties will discuss the replacement of the damaged Customer Materials and any delays to delivery of the Final Combination Product as set out in clause 4.3. |
3.6 |
Xxxx Xxxxxxx will, on termination or expiry of this Agreement, provide notice to the Customer of any Customer Materials remaining in its possession or under its control. Customer may instruct Xxxx Xxxxxxx whether to return such Customer Material to the Customer or to destroy it, at the Customer’s cost, except if the Agreement is terminated for Xxxx Xxxxxxx’x breach then it shall be at Xxxx Xxxxxxx’x cost. If the Customer does not provide instructions to Xxxx Xxxxxxx within thirty (30) days of receipt of written notice from Xxxx Xxxxxxx requesting instructions, Xxxx Xxxxxxx may dispose of the excess Customer Materials without any further liability or obligation to the Customer. |
4.1 |
No later than sixty (60) days from the Effective Date, and thereafter not less than sixty (60) days before the commencement of each calendar quarter, the |
-8 -
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
Customer shall provide Xxxx Xxxxxxx with a written non-binding forecast for the subsequent [*] specifying the Customer’s anticipated requirement for the Final Combination Product. The first [*] of any such forecast shall represent the binding quantities of the Final Combination Product which the Customer will purchase. |
4.4 |
There shall be no minimum purchase requirement from the Effective Date until the [*] anniversary of the first marketing authorisation granted for the Final |
-9 -
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
Combination Product in the United States or the European Union. Beginning in the [*] period following the [*] anniversary of such first marketing authorisation and thereafter during each period [*] following the anniversary of such date, the Customer must purchase not less than the Minimum Order Quantity of the Final Combination Product in order to maintain exclusive rights to the Device in the Field. The Minimum Order Quantity shall be reduced by agreement of the parties to take account of any unanticipated circumstances which arise that may impact the Customer’s ability to purchase the Minimum Order Quantity including any delay in or failure by Xxxx Xxxxxxx to deliver the Final Combination Product, any Force Majeure Event (as defined in clause 16) and failure to timely receive regulatory approval in any country in the Territory, any safety concerns or any restrictions on labelling or any restrictions imposed on the sale of the Final Combination Product by regulatory authorities. |
[*]
|
4.6.1 |
the Customer has not purchased the Minimum Order Quantity of Final Combination Product in any applicable [*] period as defined in clause 4.5and has not made an Order Shortfall Payment to Xxxx Xxxxxxx in accordance with clause 4.5; or |
|
4.6.2 |
no marketing authorisation has been granted in relation to the Final Combination Product in either the U.S. or Europe by the [*] anniversary of the Effective Date, |
each occurrence of the term “Field” herein (other than in clauses 1.1and 11.1) shall be substituted by the term “Limited Field” each as defined in clause 1.1. Following such substitution, the exclusivity obligations in clause 2.2 and the license grant in clause 11.5 shall be restricted to the Limited Field.
-10 -
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
reasonable details of the defect. Subject to the provisions of clause 5.3, if the Customer does not notify Xxxx Xxxxxxx of rejection of such shipment within such [*] period, such shipment of the Final Combination Product shall be deemed to have been accepted by the Customer and not to have apparent defects. |
5.2 |
For the purposes of this Agreement, “inspection” shall mean: |
|
5.2.1 |
comparing the applicable Purchase Order against the documentation accompanying the shipment to verify that the delivery date, identity, quantity and exterior shipment labelling comply with the Purchase Order; |
|
5.2.2 |
verifying that the Certificate of Conformity and Certificate of Analysis for the shipment states that the Final Combination Product conforms in all material respects to the applicable Specifications; and |
|
5.2.3 |
visually inspecting the exterior of the shipment of the Final Combination Product to verify that the shipment appears to be in good condition. |
-11 -
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
Customer including shipping charges or the cost of destruction (as Xxxx Xxxxxxx elects) in relation to such non-conforming batch (provided that [*] any Customer Materials necessary for the replacement of such Final Combination Product at its own expense unless [*]). [*]r replacement of Customer Materials shall [*]. If the parties cannot agree on whether the batch of the Final Combination Product in question conforms to the Specifications, an independent qualified laboratory reasonably acceptable to both parties, and at a cost to be borne by the party found to be in error, shall evaluate both the Customer’s and Xxxx Xxxxxxx’x samples of the Final Combination Product from the batch in question, and the definitive results of such laboratory shall be final and binding on the parties. If the batch of the Final Combination Product in question is determined to be non-conforming, such non-conforming batch shall be held for Xxxx Xxxxxxx’x disposition, or shall be returned to Xxxx Xxxxxxx, as directed by Xxxx Xxxxxxx no later than [*] following such determination, in each case at Xxxx Xxxxxxx’x expense. Xxxx Xxxxxxx shall replace each non-conforming batch of the Final Combination Product, or the non-conforming portion thereof, with conforming Final Combination Product within [*] (provided that [*] any Customer Materials necessary for the replacement of such Final Combination Product at its own expense unless [*]). [*] replacement of Customer Materials shall [*]. If the batch of the Final Combination Product in question is determined to be conforming and provided that the Certificate of Conformity did not indicate it to be non-conforming, such batch of the Final Combination Product shall be returned to the Customer at the Customer’s cost and expense. |
5.6 |
If Xxxx Xxxxxxx’x performance of its obligations under this Agreement is prevented or delayed by any breach of clauses 2, 4 or 5 as a result of any action or omission by the Customer, Xxxx Xxxxxxx will not be liable to the extent that any costs, charges or losses sustained or incurred by the Customer arose from such breach or act or omission of the Customer. For the avoidance of doubt, any defect in the Final Combination Product (whether pursuant to clause 5.1 or 5.3) caused solely by the Customer Materials shall be the responsibility of the Customer and shall not be subject to clauses 5.4 or 5.5. Where a defect in the Final Combination Product is caused solely by the Customer Materials, if requested by the Customer, Xxxx Xxxxxxx shall provide reasonable assistance to the Customer to promptly replace the defective Final Combination Product at the Customer’s expense. |
5.7 |
Provided that Xxxx Xxxxxxx complies with its obligations under clause 5.4 and 5.5 in relation to any rejected or non-conforming Final Combination Product [*] in relation to any defect or non-conformity in such Final Combination Product. |
6.2 |
Xxxx Xxxxxxx will not keep or supply any Final Combination Product that has less than [*] of its shelf life remaining as at the time of delivery to the Customer. Any out of date or damaged Final Combination Product will be immediately destroyed by Xxxx Xxxxxxx at its cost in accordance with applicable law and such destruction shall be fully documented. |
-12 -
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
7.2 |
Xxxx Xxxxxxx must notify the Customer at least [*] prior to making any change to the Specifications and/or validated processes or procedures for moulding, assembly, packaging, quality control and quality assurance operations related to the manufacturing of Final Combination Product or any services provided under this Agreement including reasonable details of the changes it is proposing to make. |
7.3 |
The Customer understands and accepts that changes to the Device, the Final Combination Product and/or Specifications may impact on regulatory or other approvals obtained by Xxxx Xxxxxxx and that as a result additional development work may be required to be undertaken. Any such development work shall be undertaken on terms (including as to cost) to be agreed between the parties provided that any changes required as a result of changes proposed by Xxxx Xxxxxxx shall be at Xxxx Xxxxxxx’x cost. |
7.4 |
Any changes may also impact on the Price payable by the Customer and any changes to the Device, Final Combination Product and/or Specifications are subject to agreement as to the Price applicable to such modified Final Combination Product. |
7.5 |
If any changes or amendments are agreed to by the parties in accordance with this clause 7, the parties will promptly confirm in writing any update to Schedules 1 and/or 2 and the relevant party will implement any changes or amendments accordingly. |
8 |
Regulatory Approvals and Compliance |
8.1 |
Xxxx Xxxxxxx will be responsible, at its cost, for preparing and maintaining all approvals and registrations of manufacturing facilities and quality assurance systems required for the manufacture of Devices and the assembly and supply of the Final Combination Product under this Agreement. |
8.2 |
The Customer shall use reasonable efforts to advise Xxxx Xxxxxxx in a timely fashion of any regulatory submissions relating to the Final Combination Product which may result in inquiries from the regulatory authorities requiring responses from Xxxx Xxxxxxx. Xxxx Xxxxxxx shall use reasonable efforts to promptly respond to any such inquiries and provide all information requested by such regulatory authorities, which shall be within: (i) [*] from Xxxx Xxxxxxx'x receipt of the inquiry; or (ii) the timeframe set forth by such regulatory authorities, whichever is shorter. |
-13 -
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
8.5 |
Xxxx Xxxxxxx will maintain, in sufficient detail and in accordance with GMP, comprehensive, accurate and up to date validation documents and production records relating to the manufacture of the Device and the assembly of the Final Combination Product and will provide copies of these to the Customer on request. |
8.6 |
Xxxx Xxxxxxx will ensure that it, and any sub-contractor conducting any of the manufacture and supply, has in place (and maintains during the period that it is conducting any manufacture or supply) all approvals, permits and licences relating to the premises where any of the manufacture and/or supply is taking place as are required for the manufacture of the Device and/or the assembly of the Final Combination Product intended for use in the administration of human medicinal products. |
9.1 |
Xxxx Xxxxxxx will permit the Customer, its representatives and any regulatory authorities to: |
|
9.1.1 |
inspect Xxxx Xxxxxxx’x work under this Agreement and its manufacturing facilities; |
|
9.1.2 |
inspect all relevant records of Xxxx Xxxxxxx relating to the manufacture of the Devices and/or the assembly and supply of the Final Combination Product; and |
|
9.1.3 |
access relevant representatives of Xxxx Xxxxxxx. |
Such inspections by the Customer or its representatives will take place during regular business hours and require reasonable prior notice to Xxxx Xxxxxxx and may take place no more than [*] during the Term with the exception of audits or inspections required by regulatory authorities, in response to or following a recall as set out in clause 14 or a prior audit at which issues were identified. The Customer will provide Xxxx Xxxxxxx with the identity of its representatives in advance and Xxxx Xxxxxxx will accept such representatives unless it has objectively valid reasons for not doing so.
-14 -
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
but only in consultation with and after consent of Xxxx Xxxxxxx, such consent not to be unreasonably withheld, delayed or conditioned. |
9.3 |
Xxxx Xxxxxxx shall provide the Customer, promptly after receipt by Xxxx Xxxxxxx, with a summary of any inspection reports and/or legal actions with or by any regulatory authority relating to the manufacture of Devices or assembly of Final Combination Product. |
9.4 |
In connection with any pre-approval inspections by any regulatory authority of Xxxx Xxxxxxx’x facilities where manufacturing, storage or testing of Devices or Final Combination Product or their components takes place, Xxxx Xxxxxxx shall permit appropriate Customer personnel to be present during such inspection and shall provide the Customer with timely communication and updates on pre-approval inspections by any regulatory authority for the Devices or Final Combination Product. In addition, Xxxx Xxxxxxx shall keep the Customer timely and reasonably informed on an on-going basis as to any proposed responses regarding corrective or remedial actions to be taken as a result of any such pre-approval inspection, including, without limitation, any corrective or remedial action relating to Xxxx Xxxxxxx'x facilities or any third party's facilities used for the benefit of Xxxx Xxxxxxx. |
9.5 |
The rights of access and information granted under this clause 9 will be without prejudice to the obligations of confidentiality contained elsewhere in this Agreement. |
10.1 |
In consideration of the supply of the Final Combination Product in accordance with this Agreement by Xxxx Xxxxxxx, Xxxx Xxxxxxx will be entitled to invoice the Customer for the Price. Xxxx Xxxxxxx shall be entitled to invoice the Price following delivery of the Final Combination Product to the Customer in accordance with clause 4. |
10.3 |
The Customer will pay each invoice in U.S Dollars to the bank account specified in Schedule 2 or as is otherwise nominated in writing on the relevant invoice or by Xxxx Xxxxxxx from time to time. |
|
10.4.1 |
the Exchange Rate as at the Exchange Rate Comparison Date; |
|
10.4.2 |
the average Exchange Rate during the relevant [*] period; and |
|
10.4.3 |
the difference between the two Exchange Rates (expressed as a percentage) (the “Exchange Rate Percentage Difference”); and |
|
10.4.4 |
the “Price Adjustment”, being the Price multiplied by the Exchange Rate Percentage Difference. |
-15 -
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
10.6 |
All sums due under this Agreement are exclusive of any applicable value added or other sales tax, which the Customer will pay in addition at the rate prescribed by law. The invoice shall be paid in full and the Customer has no right to withhold taxes, currency conversion charges or any other sums for payment due under invoice. |
10.7 |
If any payment to Xxxx Xxxxxxx under this Agreement is overdue, Xxxx Xxxxxxx may charge the Customer interest on any overdue sum at the rate of [*] above the base rate quoted by Barclays Bank Plc from time to time provided that if the payment of any amount is disputed by the Customer, the Customer shall only be obliged to pay the amount of the invoice not in dispute until the dispute has been resolved. In the case of dispute, interest shall only be payable on the amount which is not disputed unless the Customer is found to be liable for the amount due in which case the Customer shall reimburse Xxxx Xxxxxxx for the amount outstanding plus interest at the rate set out above from the date the original invoice was due to the actual date of payment. |
10.8 |
If any Customer payment under this Agreement is at least [*] overdue, Xxxx Xxxxxxx may, at its sole discretion, suspend work on manufacture and/or supply of Final Combination Product in accordance with any other Purchase Order until the payment has been made in full. |
-16 -
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
licence to any Customer Primary Packaging, Secondary Packaging, labelling, leaflets, trademarks or trade names where such licence is required for the manufacture of the Devices and the assembly and supply of the Final Combination Product. |
11.6 |
Each party grants to the other party a non-exclusive, royalty-free, sub-licensable licence under its interest in the Joint IPR to the extent necessary to complete all activities contemplated under this Agreement (which shall include, in the case of Xxxx Xxxxxxx’x activities, the right to sub-licence to its sub-contractors). |
|
11.9.1 |
propose a re-design of the Device and/or the Final Combination Product to avoid the infringement or potential infringement; |
|
11.9.2 |
enter into negotiations with such third party to obtain a licence to allow Xxxx Xxxxxxx to manufacture the Device and/or assemble and supply the Final Combination Product to the Customer and the Customer to use and sell the Final Combination Product in the Field; or |
Until such redesign is complete or infringement avoided the Customer shall be relieved of its obligation to purchase the Minimum Order Quantity (which shall be reduced on a pro rata basis) and Xxxx Xxxxxxx shall be relieved of its obligation to supply the Final Combination Product.
11.10 |
Xxxx Xxxxxxx does not make any representation and gives no warranty that the use of the Final Combination Product by the Customer or any other person will |
-17 -
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
not infringe the Intellectual Property Rights or other rights of any third party and Xxxx Xxxxxxx will have no liability to the Customer for any such claim. |
11.11 |
The Customer does not make any representation and gives no warranty that the manufacture of the Device and/or the assembly and supply of the Final Combination Product by Xxxx Xxxxxxx or any other person will not infringe the Intellectual Property Rights or other rights of any third party and the Customer will have no liability to Xxxx Xxxxxxx for any such claim. |
11.12 |
Customer warrants at the Effective Date that, as far as it is aware, there are no third party Intellectual Property Rights or restrictions affecting the use or supply of the Customer Materials or Customer Confidential Information. |
11.13 |
Xxxx Xxxxxxx warrants at the Effective Date that, as far as it is aware, there are no third party Intellectual Property Rights or restrictions affecting the manufacture of the Devices, the assembly of the Final Combination Product or the use or supply of the Final Combination Product by or to the Customer. |
12.2 |
Notwithstanding clause 12.1 the receiving party may disclose the Confidential Information of the disclosing party to those of its employees or sub-contractors who reasonably need to know it in order to fulfil the receiving party’s obligations under this Agreement, provided that they are informed of the confidential nature of the Confidential Information and are bound by obligations of confidence no less onerous than those set out in this Agreement in respect of it. The receiving party will be liable to the disclosing party for any unauthorised disclosure or use of its Confidential Information by any of its employees or sub-contractors. |
12.3 |
The obligations of confidence and non-use set out in clause 12.1 will not apply to any Confidential Information that the receiving party can show by reference to written records: |
|
12.3.1 |
was, at the time of disclosure to the receiving party, published, known publicly or otherwise in the public domain; |
|
12.3.2 |
is, after disclosure to the receiving party, published or becomes known publicly or otherwise becomes part of the public domain, through no fault of the receiving party, any of its Affiliates, any of its sub-contractors or any of their respective employees; |
|
12.3.3 |
was, prior to the time of disclosure to the receiving party, known to and at the free disposal of the receiving party; |
|
12.3.4 |
is, at any time, disclosed to the receiving party by a third party in circumstances in which the receiving party has no reason to believe that there has been a breach of an obligation of confidence owed to the disclosing party; |
|
12.3.5 |
is independently developed by or on behalf of the receiving party without use of or reliance on the Confidential Information received from the disclosing party. |
-18 -
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
12.4 |
Neither party will be in breach of its obligations under clause 12.1 to the extent that it is required to disclose any Confidential Information of the other under any law or by or to a court or other public, regulatory or financial authority that has jurisdiction over it, provided that the receiving party gives the disclosing party written notice prior to disclosing any of the disclosing party’s Confidential Information and that the disclosure is made only to the extent required and for the purpose of complying with the requirement and that the receiving party takes all reasonable measures to ensure, as far as it is possible to do so, the continued confidentiality of any Confidential Information so disclosed. |
12.5 |
Except as required to comply with applicable laws and regulations relating to the sale of the Final Combination Product (including, for the avoidance of doubt, any requirement for the Customer to refer to Xxxx Xxxxxxx as the manufacturer of the Final Combination Product), neither party will use the other’s name or logo in any press release or product advertising, or for any other promotional purpose, without first obtaining the other’s written consent. |
|
13.3.1 |
promptly notify the indemnifying party in writing with details of the claim; |
-19 -
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
|
13.3.3 |
allow the indemnifying party to have the conduct of the defence or settlement of the claim; and |
|
13.3.4 |
give the indemnifying party all reasonable assistance (at the indemnifying party’s expense) in dealing with the claim. |
13.4 |
In the event the party claiming the indemnity under clauses 13.1 and 13.2 fails to comply with clause 13.3 the amount that party may claim under the indemnity shall be reduced to take into account any additional loss that may have resulted in the claiming party’s non-compliance with clause 13.3. |
|
13.7.1 |
death or personal injury caused by its negligence; |
|
13.7.2 |
any fraud by that party; or |
|
13.7.3 |
any sort of liability that, by law, cannot be limited or excluded. |
13.8 |
The express undertakings and warranties given by the parties in this Agreement are in lieu of all other warranties, conditions, terms, undertakings and obligations whether express or implied by statute, common law, custom, trade usage, course of dealing or in any other way. All of these are expressly excluded from this Agreement to the full extent permitted by law. |
13.9 |
During the Term and for a period of [*] years after the expiry or termination of this Agreement, each party will maintain with a reputable insurance company comprehensive third party liability insurance including, without limitation, insurance of product liability with cover of at least [*] per claim and in aggregate per year. Each party will, at the request of the other, provide documentary evidence confirming the maintenance of such cover. |
-20 -
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
statements, reports, tests and other relevant information so far as such is reasonably necessary. Any supply of information or provision of assistance under this clause 13.10 shall not constitute an assumption of liability with respect to such incident or side effect. Any admission or declaration of liability in relation to any incident or side effect shall only be made with the other party’s prior written consent. |
14.4 |
If a competent authority requires a recall of the Final Combination Product, the parties shall cooperate in good faith to implement such recall provided always that the Customer shall have the right to control all recalls, product withdrawals and field corrections for the Final Combination Product. If the recall was caused: |
|
14.4.1 |
solely or predominantly by Xxxx Xxxxxxx’x failure to supply the Final Combination Product in accordance with the Specification or the provisions of this Agreement, the Customer shall be entitled to set its reasonable expenses incurred in a recall against its future payments due to Xxxx Xxxxxxx hereunder or, on request, to be reimbursed by Xxxx Xxxxxxx within [*] of the date of the Customer’s written request; or |
|
14.4.2 |
solely or predominantly by the Customer Materials, Xxxx Xxxxxxx shall be entitled to invoice the Customer for its reasonable expenses incurred in a recall. |
-21 -
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
15.1 |
This Agreement will come into force on the Effective Date and will remain in force for a period ending on the date falling ten (10) years from the date on which the first shipment of Final Combination Product is accepted by Customer unless terminated earlier by either party in accordance with any other provision of this Agreement (the “Term”). No later than [*] before the end of the Term the parties may agree in writing to continue the Agreement for an additional [*] or such other period as the parties may agree. |
15.2 |
Either party may (without limiting any other remedy it may have) at any time terminate this Agreement with immediate effect by giving written notice to the other if: |
|
15.2.1 |
the other is in material breach of any provision of this Agreement and, if it is capable of remedy, the breach has not been remedied within [*] after receipt of written notice specifying the breach and requiring its remedy; or |
|
15.2.2 |
the other party becomes insolvent, or if an order is made or a resolution is passed for its winding up (except voluntarily for the purpose of solvent amalgamation or reconstruction), or if an administrator, administrative receiver or receiver is appointed over the whole or any part of the other party’s assets, or if the other party makes any arrangement with its creditors or ceases to carry on business or does or suffers any similar or analogous act existing under the laws of any country. |
15.3 |
Either party may terminate this Agreement at any time without cause by giving not less than twelve (12) months’ written notice to the other party. |
15.4 |
In the event of termination of this Agreement by the Customer in accordance with clause 15.2 or Xxxx Xxxxxxx in accordance with clause 15.3: |
|
15.4.1 |
Xxxx Xxxxxxx shall continue to manufacture the Devices and assemble and supply the Final Combination Product to the Customer in accordance with the terms of this Agreement and the Customer shall be permitted to continue to sell the Final Combination Product until the Customer is able to identify, appoint, and qualify through all necessary regulatory approvals a third party manufacturer to supply product equivalent to the Devices and the Final Combination Product in place of Xxxx Xxxxxxx; and |
|
15.4.2 |
on such commercial terms as the parties may agree (and subject to the negotiation and agreement of such commercial terms) Xxxx Xxxxxxx will provide to the Customer such assistance, documentation and licences under Xxxx Xxxxxxx’x relevant Intellectual Property Rights as may reasonably be required by the Customer or the third party manufacturer to enable the third party manufacturer to manufacture products equivalent to the Devices and the Final Combination Product (any such documentation shall be the Confidential Information of Xxxx Xxxxxxx and such provision will be subject to the Customer and such third party manufacturer entering such binding obligations of confidence and non-use as Xxxx Xxxxxxx may reasonably require in relation to such documentation and subject to the Customer ceasing to manufacture or have manufactured such Final Combination Products on the date on which the Term would have ended had the Agreement not been terminated); and |
-22 -
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
15.5 |
In the event of termination of this Agreement by Xxxx Xxxxxxx in accordance with clause 15.2 or by the Customer in accordance with clause 15.3, Xxxx Xxxxxxx shall have no obligation to provide the Customer with any assistance, documentation or license to allow for the transfer of the manufacture of the Final Combination Product to any third party, but may at its option do so subject to such commercial terms as the parties may agree. |
15.6 |
On termination or expiry of this Agreement for any reason: |
|
15.6.1 |
all invoices shall become immediately due and payable in accordance with the payment terms set out in clause 10; |
|
15.6.3 |
all licences shall immediately cease as at date of termination or expiry save where continuation of such licences is necessary for: (a) Xxxx Xxxxxxx to comply with its obligations under clauses 15.4 or 15.6.2; or (b) for the Customer to meet any third party orders for Final Combination Product existing as of the date of termination or expiry (save that such right shall only apply for a period of [*] from the date of termination or expiry); |
|
15.6.4 |
any regulatory approvals relating to the Device or the Final Combination Product held by Xxxx Xxxxxxx shall be immediately transferred to the Customer, at the Customer’s sole cost. Xxxx Xxxxxxx shall provide the Customer with any assistance necessary and execute any documents required to transfer the regulatory approvals to the Customer; |
|
15.6.5 |
the Confidential Information of the parties shall be returned to the other party in accordance with clause 12.6. |
15.7 |
Termination of this Agreement will not release any party from any obligation or liability which has fallen due or arisen before the effective date of termination of the Agreement. |
15.8 |
Clauses 1, 10, 11, 12, 13, 14, 15, and 17 will survive termination of this Agreement for whatever reason. |
-23 -
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
notice of that Force Majeure Event to the other party as soon as practicable, indicating the nature, effect and likely duration of that Force Majeure Event. |
16.2 |
The performance of the affected party’s obligations, to the extent affected by the Force Majeure Event, will be suspended during the period that the Force Majeure Event persists, provided that if performance is not resumed within three (3) months either party may, at any time prior to the resumption of the obligations, terminate this Agreement with immediate effect by giving written notice to the other party. |
17.1 |
Each party shall comply with all applicable laws in the course of performing its obligations or exercising its rights pursuant to this Agreement. Each party undertakes to comply with the provisions of any applicable law intended to prevent corruption and/or bribery (collectively “Compliance Laws”) and to adopt all appropriate measures to prevent violation of the Compliance Laws. Without limiting the foregoing, either party agrees that it will not, in the conduct of its performance under this Agreement, offer, pay, give or promise to pay or give, directly or indirectly, any payment or gift of any money or thing of value to: (i) any government official to influence any acts or decisions of such official or to induce such official to use his influence with any government to effect or influence the decision of such government in order to assist the party in its performance of its obligations under this Agreement or to benefit either of the parties; (ii) any political party or candidate for public office for such purpose; or (iii) any person if such party knows or has reason to know that such money or thing of value will be offered, promised, paid or given, directly or indirectly, to any official, political party or candidate for such purpose. |
17.2 |
Notices: Any notice to be given under this Agreement must be in writing, may be delivered to the other party by any of the methods set out in the left hand column below, and will be deemed to be received on the corresponding day set out in the right hand column: |
Method of service
|
Deemed day of receipt |
By hand or courier
|
the day of delivery |
By pre-paid first class post
|
the second Business Day after posting |
By recorded delivery post
|
the next Business Day after posting |
By fax (provided the sender’s fax machine confirms complete and error-free transmission of that notice to the correct fax number) |
the next Business Day after sending or, if sent before 16.00 (sender’s local time) on the Business Day it was sent
|
The parties’ respective representatives for the receipt of notices are, until changed by notice given in accordance with this clause, as follows:
For Xxxx Xxxxxxx: |
For the Customer: |
-24 -
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
Name: Xxxxx Xxxxx
Address: XxxxxXxxx Xxxxxxxxx XX00 0XX
|
Address: 0000 Xxxxxxxx Xxxxx Xxxxx 000 Xxxxx Xxxx XXX
|
Fax number: x0 000-000-0000 |
17.3 |
Assignment/sub-contracting: Neither party may assign or transfer this Agreement as a whole, or any of its rights or obligations under it, without first obtaining the written consent of the other party (not to be unreasonably withheld or delayed) provided that: |
|
17.3.1 |
either party may, without the consent of the other party, assign all of its rights and obligations under this Agreement to an Affiliate or to any successor to that part of its business to which the subject matter of this Agreement relates. In the event a party assigns all of its rights and obligations under this Agreement to an Affiliate and such Affiliate ceases to be an Affiliate of the party, all of the assigned rights and obligations under this Agreement shall be transferred back to the relevant party; and |
|
17.3.2 |
Customer may, without the consent of Xxxx Xxxxxxx, assign this Agreement to the purchaser or licensee in the event of the grant of a licence or sale of its business relating to the Final Combination Product. |
17.4 |
Illegal/unenforceable provisions: If the whole or any part of any provision of this Agreement is void or unenforceable in any jurisdiction, the other provisions of this Agreement, and the rest of the void or unenforceable provision, will continue in force in that jurisdiction, and the validity and enforceability of that provision in any other jurisdiction will not be affected. |
17.5 |
Waiver of rights: If a party fails to enforce, or delays in enforcing, an obligation of the other party, or fails to exercise, or delays in exercising, a right under this Agreement, that failure or delay will not affect its right to enforce that obligation or constitute a waiver of that right. Any waiver of any provision of this Agreement will not, unless expressly stated to the contrary, constitute a waiver of that provision on a future occasion. |
17.6 |
No agency: Nothing in this Agreement creates, implies or evidences any partnership or joint venture between the parties, or the relationship between them of principal and agent. Neither party has any authority to make any representation or commitment, or to incur any liability, on behalf of the other. |
17.7 |
Entire agreement: This Agreement (incorporating all Schedules) and any Quality Agreement entered into between the parties constitutes the entire agreement between the parties relating to its subject matter and supersedes all prior oral or written agreements, arrangements or understandings between them (including, without limitation, any project proposal supplied by Xxxx Xxxxxxx) relating to its subject matter. In the event that the terms of the Quality Agreement are inconsistent with the terms of this Agreement, the terms of this Agreement shall prevail. Each party acknowledges that it has not entered into this Agreement on the basis of any warranty, representation, statement, agreement or undertaking except those expressly set out in this Agreement. Each party waives any claim for breach of this Agreement, or any right to rescind this Agreement in respect of, any representation which is not an express provision of this Agreement. However, this clause does not exclude any liability which either party may have to the other (or any right which either party may have to rescind this Agreement) in respect of any fraudulent misrepresentation or fraudulent concealment prior to the execution of this Agreement. |
-25 -
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
17.8 |
Formalities: Each party will take any action and execute any document reasonably required by the other party to give effect to any of its rights under this Agreement, or to enable their registration in any relevant jurisdiction within the Territory provided the requesting party pays the other party’s reasonable expenses. |
17.9 |
Amendments: No variation or amendment of this Agreement (including the Schedules) will be effective unless it is made in writing and signed by each party’s representative. |
17.10 |
Third parties: No one except a party to this Agreement has any right to prevent the amendment of this Agreement or its termination, and no one except a party to this Agreement may enforce any benefit conferred by this Agreement, unless this Agreement expressly provides otherwise. The indemnified parties specified in clauses 13.1and 13.2 may directly enforce the indemnities in those clauses. |
17.11 |
Governing law: This Agreement is governed by, and is to be construed in accordance with, [*] law. The [*] Courts will have exclusive jurisdiction to deal with any dispute which has arisen or may arise out of or in connection with this Agreement, except that either party may bring proceedings for an injunction in any jurisdiction. |
SIGNED by the authorised representatives of the parties on the date set out at the head of this Agreement.
SIGNED for and on behalf of XXXX XXXXXXX LIMITED:
Name Xxxxx Xxxxx
Position Group Finance Director
Signature /s/ Xxxxx Xxxxx |
SIGNED for and on behalf of VERSARTIS GMBH:
Name Xxxx X. Xxxxxxxx
Position Managing Director
Signature /s/ Xxxx X. Xxxxxxxx
|
-26 -
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
SCHEDULE 1
Part 1
Device
Description of device, including drawings highlighting any special features will be agreed by Owne Mumford and Customer before commencement of manufacturing of the Device.
Part 2
Labelling and Packaging Specifications
Details of the Labelling and Packaging Specifications (including any branding requirements) for both Primary and Secondary Packaging will be agreed by Xxxx Xxxxxxx and Customer before commencement of manufacturing of the Device.
Part 3
Final Combination Product
Details of the Final Combination Product (including any branding requirements) will be agreed by Xxxx Xxxxxxx and Customer before commencement of manufacturing of the Final Combination Product.
Part 4
Quality Agreement and Specifications and Assumptions
Within 90 days of the Effective Date, Xxxx Xxxxxxx and Customer will execute a Quality Agreement related to manufacture of the Device and the Final Combination Product. Before commencement of manufacturing of the Device, the parties will agree technical specifications and design specifications relating to the Device and the Final Combination Product.
-27 -
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
SCHEDULE 2
Price and Payment Schedule
Provisional Price for each of the Final Combination Product based on the device being packed in a twin pack:
|
Price (Pounds Sterling) |
|||
|
Subassemblies |
Assembly |
Packaging |
Total |
Initial Production up to [*] units |
[*] |
[*] |
[*] |
[*] |
Routine Production <[*] |
[*] |
[*] |
[*] |
[*] |
>[*] |
[*] |
[*] |
[*] |
[*] |
>[*] |
[*] |
[*] |
[*] |
[*] |
>[*] |
[*] |
[*] |
[*] |
[*] |
This pricing does include batch release testing with the exception of drug testing.
The parties shall agree a fixed Price for the Final Combination Products prior to production.
The parties shall meet within [*] before or after [*], and each [*] anniversary of that date (in each case the “Anniversary”) to review the Price in good faith.
If within one month of meeting to review the Price the parties cannot agree a revised Price, then, on such date of the Price will [*] between the date on which the Price was last set or increased and the date on which Xxxx Xxxxxxx increases the Price.
Once the new Price is agreed or determined, it shall apply with effect from the relevant Anniversary and shall be deemed to come into force from that date (which, for the avoidance of doubt, may have retrospective effect if the parties meet, or if the Price is agreed or determined, after the relevant Anniversary). Within one month of agreeing or determining the new Price, the Customer shall pay to Xxxx Xxxxxxx any outstanding sums due in respect of its purchases of Products since the relevant Anniversary, together with any applicable VAT.
The Customer’s address for the receipt of invoices under this Agreement is:
Accounts Payable
0000 Xxxxxxxx Xxxxx, Xxxxx 000
Xxxxx Xxxx, XX 00000
XXX
or
xx@xxxxxxxxx.xxx
134906374 v2
-28 -
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.